ALDEYRA THERAPEUTICS, INC. (ALDX) Operating income 2016–2025
ALDEYRA THERAPEUTICS, INC. (ALDX) annual operating income history from SEC filings — each fiscal year as reported.
-$35.3MFY2025 · since FY2016: -$18.7M → -$35.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$35.3M | +41.3% |
| FY2024 | -$60.1M | -40.5% |
| FY2023 | -$42.8M | +31.7% |
| FY2022 | -$62.7M | -11.5% |
| FY2021 | -$56.2M | -54.4% |
| FY2020 | -$36.4M | +42.3% |
| FY2019 | -$63.1M | -58.9% |
| FY2018 | -$39.7M | -76.5% |
| FY2017 | -$22.5M | -20.3% |
| FY2016 | -$18.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALDX financial trends
ALDX RevenueALDX Net incomeALDX Net marginALDX Gross profitALDX Gross marginALDX Operating marginALDX Operating cash flowALDX Free cash flowALDX Capital expendituresALDX Return on equityALDX Stock buybacksALDX Dividends paidALDX Total assetsALDX Total liabilitiesALDX Shareholders’ equityALDX overview →